The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients
about
Cytotoxic and antiangiogenic paclitaxel solubilized and permeation-enhanced by natural product nanoparticles.Clinical studies with oral lipid based formulations of poorly soluble compoundsPaclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice.Intelligent hydrogels for the oral delivery of chemotherapeutics.A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer.Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients.Investigation of the micellar effect of pluronic P85 on P-glycoprotein inhibition: cell accumulation and equilibrium dialysis studies.Intravenous-to-oral switch in anticancer chemotherapy: a focus on docetaxel and paclitaxel.Local delivery of paclitaxel in the treatment of peripheral arterial disease.Effects of Adamantyl Derivatives on Pharmacokinetic Behavior of Paclitaxel in Rats.Kinetics of petroleum oil biodegradation by a consortium of three protozoan isolates (Aspidisca sp., Trachelophyllum sp. and Peranema sp.).Inhalable, large porous PLGA microparticles loaded with paclitaxel: preparation, in vitro and in vivo characterization.Membrane Assays to Characterize Interaction of Drugs with ABCB1.Formulation studies of InhA inhibitors and combination therapy to improve efficacy against Mycobacterium tuberculosis.Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor ELUse of Tween 40 and Tween 80 to deliver a mixture of phytochemicals to human colonic adenocarcinoma cell (CaCo-2) monolayers.In vitro and in vivo evaluation of effect of excipients in local delivery of paclitaxel using microporous infusion balloon catheters.
P2860
Q34747035-4ED3A1EB-7E58-4785-82D2-534E4F405D37Q34778043-677034B2-BD27-49D2-997F-B1A470401179Q35178040-3F37E66F-0EEA-4E78-B8E9-407DF6921049Q36316917-7B3C097B-325B-4980-AF8A-0AB900BB45B4Q36611637-3875DB79-8E13-4259-8EA8-1E2F0DEF3E65Q37282649-00D38C72-987A-4B46-A64A-67A0D4192A83Q37371578-A07AB575-0D7A-4D63-B5FB-66B3A5132443Q37634957-61EC19DB-6E68-42F3-B9D4-5EB09A339A12Q38329893-7C9E09DF-39B6-416C-9245-4BACFBF300F8Q38405976-50C27309-E6F1-4B25-8CFC-E347F8790205Q38608894-00B24D66-F3F0-4299-97D7-9D4E4DE8997DQ38831758-F490C937-85B4-4659-B152-48640B0DC225Q38880731-1B2A2CDB-9E36-493F-BD30-6B75C6E968C8Q40444230-FDB927F3-D633-4DA8-81EA-E332CDACF847Q42759005-9DC2916F-16FC-4C8B-A54E-AFE7D7677B91Q44892169-2F2A5C08-5CB7-4F72-9760-036CF7938632Q51667021-67D88EB5-918C-497A-8BFA-8EF1179BD195
P2860
The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The co-solvent Cremophor EL li ...... paclitaxel in cancer patients
@ast
The co-solvent Cremophor EL li ...... paclitaxel in cancer patients
@en
The co-solvent Cremophor EL li ...... paclitaxel in cancer patients
@nl
type
label
The co-solvent Cremophor EL li ...... paclitaxel in cancer patients
@ast
The co-solvent Cremophor EL li ...... paclitaxel in cancer patients
@en
The co-solvent Cremophor EL li ...... paclitaxel in cancer patients
@nl
prefLabel
The co-solvent Cremophor EL li ...... paclitaxel in cancer patients
@ast
The co-solvent Cremophor EL li ...... paclitaxel in cancer patients
@en
The co-solvent Cremophor EL li ...... paclitaxel in cancer patients
@nl
P2093
P2860
P356
P1476
The co-solvent Cremophor EL li ...... paclitaxel in cancer patients
@en
P2093
F J Koopman
H A Bardelmeijer
J H Beijnen
J H Schellens
M M Malingré
M Ouwehand
O Van Tellingen
W W Ten Bokkel Huinink
P2860
P2888
P304
P356
10.1054/BJOC.2001.2118
P407
P577
2001-11-16T00:00:00Z
P5875
P6179
1012599363